Chloroquine for Mild Symptomatic and Asymptomatic COVID-19

• Status: Terminated
• Trial end date: 2020-09-01
• Target enrollment: 0
• Participant gender: All

Summary

19 COVID (Coronavirus disease 2019 ) is a deadly viral disease that has been spreading around the world for several months, and is caused by a CORONA family virus (COVID-19). Following IN-VITRO evidence of the antiviral effect of CHLOROQUINE in CORONA viruses, this drug has been used empirically for COVID-19 patients and is currently recommended in Israel for the treatment of intermediate and severity disease.

The mechanism of action of chloroquine is in part by inhibiting the virus distribution, and changing the intracellular acidity, the virus distribution site. The intracellular chloroquine concentration is determined by a pump called PGP (permeability glycoprotein) that removes the drug from the cell and is activated by the drug. In the treatment of malaria, the benefit of low dosage of the drug has been shown to be effective due to the fact that the intracellular concentration of the drug is probably higher, and therefore the logic to examine this issue in COVID-19 treatment.

The purpose of this study is to test whether a low dose of Chloroquine will reduce the duration of the viral shedding and prevent the disease from worsening.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: HaEmek Medical Center, Israel
• Collaborator: T MAY BIOPHARMA LTD.
• Treatments: Chloroquine; Chloroquine diphosphate

Criteria

Inclusion Criteria:

• Age over 18

• A person diagnosed with COVID-19 in the past 48 hours

• Asymptomatic

Exclusion Criteria:

• chronic lung disease with chronic hypoxia

• Sleep apnea requiring BIPAP / continuous positive airway pressure

• Retinal disease

• Porphyria

• Myastenia gravis

• immunodeficiency disorders

• Hearing Disorders

• Scheduled for general anesthesia

• treatment with antibiotics or antiretroviral for any reason

• Pulse <50

• Known Ventricular arrhythmias

• Heart Failure: Systolic or Diastolic

• kown QT prolongation

• Taking medicines that increase the risk of QT prolongation in combination with CHLOROQUINE.